Safety of Combining Irinotecan With 5-FU Leucovorin/Folinic Acid Oxaliplatin and Docetaxel Chemotherapies

  • STATUS
    Recruiting
  • End date
    May 20, 2027
  • participants needed
    54
  • sponsor
    University of Chicago
Updated on 20 June 2021
measurable disease
fluorouracil
metastasis
oxaliplatin
neutrophil count
pancreatic adenocarcinoma
liver metastasis
irinotecan
primary tumor
chemotherapy regimen
adenocarcinoma
administration intravenous

Summary

The purpose of the proposed study is to establish the safety of combining irinotecan chemotherapy with 5-FU, leucovorin/folinic acid, oxaliplatin, and docetaxel (abbreviated as the I-FLOAT study of gFOLFOXIRITAX) chemotherapies (leucovorin/folinic acid is a vitamin to make 5-FU work well).

Details
Condition Carcinoma, Malignant Adenoma, Gastroesophageal Junction Adenocarcinoma, Pancreatic Adenocarcinoma, Advanced Malignancies, Adenocarcinoma of the Gastroesophageal Junction, adenocarcinomas, Adenocarcinoma, Vulvar Dysplasia and Carcinoma
Treatment docetaxel, Irinotecan, Oxaliplatin, Leucovorin, 5-fluorouracil
Clinical Study IdentifierNCT04361708
SponsorUniversity of Chicago
Last Modified on20 June 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Histologically or cytologically confirmed locally advanced or metastatic pancreatic adenocarcinoma, gastroesophageal adenocarcinoma, cholangiocarcinoma, gallbladder adenocarcinoma, ampullary carcinoma, adenocarcinoma of unclear primary (with upper GI primary suspected), or other primary GI malignancy for which the treating physician feels that I-FLOAT is a reasonable therapeutic option
Patients with a history of obstructive jaundice due to the primary tumor must have resolved to <1.5 X upper limit of normal and a metal biliary stent in place
Age greater than or equal to 18 years
Eastern Cooperative Oncology Group (ECOG) performance status =1
Life expectancy > 3 months
Adequate organ function, as defined by each of the following
Absolute neutrophil count (ANC) = 1500/uL Hemoglobin > 9g/dL (transfusion
permitted with stability for > 1 week) Platelets > 100,000/uL Total bilirubin
= 1.5 mg/dL AST and ALT = 2.5 X upper limit of normal; alkaline phosphatase =
5 X upper limit of normal, unless bone metastasis is present in the absence
of liver metastasis
AST and ALT = 5 X upper limit of normal if hepatic metastases are present
Creatinine
5 mg/dL 7. Measurable or non-measurable disease will be allowed. 8. Women of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatment. 9. Negative serum or urine B-hCG pregnancy test at screening for patients of childbearing potential 10. Patients taking substrates, inhibitors, or inducers of CYP3A4 should be encouraged to switch to alternative drugs whenever possible, given the potential for drug-drug interactions with irinotecan

Exclusion Criteria

Prior radiation therapy for any cancer
Prior chemotherapy for metastatic disease Recurrence of disease within 6 months of perioperative chemotherapy are eligible if other eligibility criteria are met
Inflammatory bowel disease (Crohn's disease, ulcerative colitis)
Diarrhea, grade 1 or greater by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, v. 4.0). Pancreatic cancer patients with clinical evidence of pancreatic insufficiency must be taking pancreatic enzyme replacement
Neuropathy, grade 2 or greater by NCI-CTCAE, v. 4.0
Documented brain metastases
Serious underlying medical or psychiatric illnesses that would, in the opinion of the treating physician, substantially increase the risk for complications related to treatment
Active uncontrolled bleeding
Pregnancy or breastfeeding
Major surgery within 4 weeks
Previous or concurrent malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or any other cancer for which the patient has been previously treated and the lifetime recurrence risk is less than 30%, and meets all other eligibility criteria
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note